CBD and Heart Health: What the Research Shows

CBD has moved from the edges of wellness culture into the pages of cardiology journals. A peer-reviewed review published in Mayo Clinic Proceedings in 2025 pulled together preclinical and clinical evidence on what CBD actually does to the cardiovascular system. The picture that emerges is genuinely interesting, though it comes with real limitations.

This post walks through what the research shows, what it doesn't show yet, and what that means if you're a CBD user who also thinks about your heart health.

How CBD Interacts with the Cardiovascular System

CBD is not THC. It doesn't bind strongly to the CB1 and CB2 cannabinoid receptors that produce psychoactive effects. Instead, CBD acts on a wider set of molecular targets that happen to be relevant to cardiovascular function.

The main pathways researchers focus on:

• TRPV1 channels: transient receptor potential vanilloid 1 channels involved in vascular tone and coronary vasodilation. Animal research found that mice without functional TRPV1 had impaired heart recovery after ischemia.
• PPARγ: a transcription factor that regulates inflammation and lipid metabolism. CBD activates it, which may contribute to its anti-inflammatory effects.
• NF-κB pathway: a key inflammatory signaling pathway. CBD inhibits it, and also prevents formation of the NLRP3 inflammasome, which drives the production of pro-inflammatory cytokines like IL-1β and IL-18.
• Antioxidant activity: CBD boosts superoxide dismutase and glutathione activity and reduces oxidative stress markers, which are central to endothelial dysfunction.

These aren't abstract mechanisms. Inflammation, oxidative stress, and vascular dysfunction are the actual biological drivers behind most major cardiovascular conditions, including atherosclerosis, heart failure, and pericarditis. That's what makes CBD a plausible candidate for cardiovascular research in the first place.

CBD and Pericarditis: The Clearest Clinical Signal So Far

The review describes pericarditis, inflammation of the pericardial sac around the heart, as the cardiovascular condition with the strongest current evidence for CBD.

In a mouse model, daily CBD injections over seven days reduced pericardial effusion from 0.26 mm to 0.12 mm and cut pericardial thickness nearly in half compared to controls. Lab analysis showed CBD suppressed macrophage secretion of IL-1β and IL-6, suggesting the anti-inflammatory pathway was at work.

That preclinical work led to the MAVERIC-Pilot trial, a phase II clinical study of CardiolRx, a pharmaceutically manufactured pure CBD solution, in 27 patients with symptomatic recurrent pericarditis. Patients were titrated up to 10 mg/kg twice daily over eight weeks. Pain scores improved by a mean of 3.7 points on the Numerical Rating Scale, dropping from 5.8 at baseline to 2.1 at week eight. The median time to reach a pain score of 2 or below was just five days. No significant changes in QTc interval were observed.

Two larger randomized controlled trials, MAVERIC-2 and MAVERIC-3, are now underway to test whether CBD can maintain remission after IL-1 inhibitor withdrawal and prevent recurrence in a broader patient population.

The significance here: current recurrent pericarditis treatment relies on corticosteroids and IL-1 inhibitors, both of which carry immunosuppressive risks and high recurrence rates when stopped. If the ongoing trials confirm the MAVERIC-Pilot results, CBD would offer a non-immunosuppressive alternative. That's a meaningful therapeutic gap.

CBD and Heart Attacks: What Preclinical Research Found

Ischemia-reperfusion injury (the tissue damage that happens when blood flow is restored after a blockage) is a major contributor to heart attack outcomes. Several preclinical studies have tested whether CBD can limit that damage.

In one study, CBD administered at 5 mg/kg daily for seven days before a 30-minute coronary artery ligation reduced infarct size by 66% compared to controls, alongside measurable reductions in myocardial inflammation and IL-6 levels. Notably, the effect disappeared in isolated ex-vivo hearts, which suggests CBD may work through systemic anti-inflammatory actions rather than direct cardiac effects alone.

A rabbit model found similar results. CBD administered before reperfusion enhanced blood flow to the area at risk, increased perfusion density by 1.7-fold, and reduced the infarction core relative to the area at risk. Cardiac MRI showed improved systolic wall thickening and a significant reduction in microvascular obstruction.

CBD also showed neuroprotective effects against ischemia-reperfusion injury in animal models, which may matter for brain events that accompany or follow cardiac events.

None of this has been tested in a human clinical trial for heart attacks yet. The acute nature of myocardial infarction and the existence of well-established treatment protocols make that logistically complicated. But the preclinical signal is consistent across multiple animal models.

CBD and Blood Pressure: A Human Trial With Real Numbers

This is where the clinical evidence gets more concrete for everyday CBD users.

A randomized, placebo-controlled crossover study in 70 patients with mild to moderate hypertension tested CBD at up to 5 mg/kg per day for five weeks. CBD significantly reduced 24-hour ambulatory mean, systolic, and diastolic blood pressure at 2.5 weeks. No serious adverse effects were reported.

A smaller study in nine healthy volunteers who received a single 600 mg dose found a 6 mmHg reduction in resting systolic blood pressure, plus attenuated blood pressure responses to mental stress, exercise, and cold stress. Post-hoc analysis showed reductions in mean arterial pressure, diastolic pressure, total peripheral vascular resistance, and stroke volume.

The review authors are careful to note that CBD's anxiolytic properties may contribute to these effects, so it's not certain these are purely direct vascular actions. The doses used in trials are also significantly higher than what's typically in an OTC CBD gummies serving or a daily tincture dose. Still, the human data on blood pressure is stronger than in most other cardiovascular areas.

CBD and Arrhythmias: The Evidence Points in Both Directions

This section is worth reading if you have any history of arrhythmias or if you're on anti-arrhythmic medications.

On one side: in vitro studies found that CBD prolongs the cardiac action potential and QT interval by suppressing delayed rectifier potassium channels. Another in vitro study found CBD inhibits Nav1.5 sodium current and L-type calcium current, which could be pro-arrhythmic in people with certain inherited ion channel disorders.

On the other side: in an animal model, CBD administered before coronary occlusion significantly reduced the incidence of ischemia-induced ventricular arrhythmias, including ventricular tachycardia. The MAVERIC-Pilot trial in humans found no significant QTc changes.

The review's conclusion here is appropriately cautious: CBD is unlikely to provide direct clinical benefit for arrhythmia treatment, but it doesn't appear to be consistently pro-arrhythmic either. The bigger concern is drug interactions, covered below.

Heart Failure and Cardiomyopathy: Preclinical Promise, No Human Trials

Several preclinical studies have examined CBD in the context of heart failure and cardiomyopathy. The mechanisms overlap with what makes CBD interesting for IHD and pericarditis: anti-inflammatory effects, antifibrotic effects, and antioxidant activity.

In a rat model of doxorubicin-induced cardiac injury (a serious complication of some cancer chemotherapies), CBD at 5 mg/kg daily reduced markers of cardiac tissue damage. In diabetic cardiomyopathy mouse models, CBD attenuated hyperglycemia-induced oxidative stress, reversed diabetes-related myocardial changes, and improved both systolic and diastolic function.

On the myocarditis side, a study in animal models of autoimmune myocarditis found that CBD significantly reduced inflammatory cell infiltration in heart tissue, decreased expression of CD4, CD8, IL-1β, and IL-6, and produced substantial improvements in both systolic and diastolic cardiac function. The mechanism appeared to involve CBD's antioxidant and antifibrotic effects alongside reduction of oxidative stress.

The ARCHER trial is the first randomized controlled study of CBD in human myocarditis. It's a phase 2, double-blind, placebo-controlled trial in patients with mild to moderate acute myocarditis who receive CBD or placebo on top of standard heart failure therapies. Results have not yet been published.

A new subcutaneous CBD formulation called CRD-38 is in early development, with phase 1 trials planned specifically for heart failure.

No human clinical data exists yet for heart failure or cardiomyopathy applications outside of early-phase studies. All of this remains in the preclinical and emerging-clinical stage, with the most direct benefit pathway still requiring large multicenter randomized trials to establish.

What the Research Hasn't Figured Out Yet

The review is honest about the gap between preclinical promise and clinical confirmation. Here's where the limitations are real:

Dosing is all over the place. Doses used across studies range from 50 micrograms per kilogram intravenously to 10 mg/kg injections. Route of administration varies too, including intravenous, intraperitoneal, oral, transdermal, and inhaled. Oral bioavailability is as low as 6%, while inhalation runs 11% to 45%, and taking CBD with a high-fat meal can increase plasma concentrations by four to five times. These differences make it genuinely hard to compare results across studies or to connect preclinical findings to human OTC products. The cardiovascular trials currently underway use titrated oral doses, which is more applicable to consumer products, but standardized dosing protocols for cardiovascular indications don't yet exist.

Drug interactions are a real concern. CBD inhibits several CYP450 enzymes, meaning it can alter the metabolism of drugs that many cardiovascular patients take. The list includes warfarin (CYP2C9), amiodarone (CYP2C9), clopidogrel (CYP2B6), dronedarone, statins including lovastatin and simvastatin (CYP3A4), and beta-blockers including metoprolol and nebivolol (CYP2D6). If you're on any of these medications, this is a conversation to have with your prescriber before adding CBD.

Liver safety at high doses. One trial using 20 mg/kg/day of CBD observed drug-induced liver injury in 31% of participants (defined as serum alanine aminotransferase greater than five times the upper limit of normal). That's a high dose, significantly above typical consumer product doses, but it's worth noting that Epidiolex (FDA-approved CBD for epilepsy) raised similar concerns at therapeutic doses.

OTC products are underdosed relative to trials. An international analysis found that typical listed daily doses in commercially available oils and capsules are under 150 mg, which is substantially lower than the therapeutic doses being evaluated in cardiovascular trials. This doesn't mean consumer products are without effect, but it does mean you shouldn't assume OTC doses translate directly to trial outcomes.

What This Means for CBD Users

The research is real and it's encouraging, especially for pericarditis and ischemia-reperfusion injury. But it's still early, with most human evidence limited to small trials and the most promising applications still in phase 2 or 3.

A few practical takeaways:

• If you take cardiovascular medications, warfarin and beta-blockers in particular, mention your CBD use to your prescriber. The interaction potential is real even if the clinical magnitude hasn't been precisely quantified.
• Product quality matters. CBD products vary widely in purity and actual cannabinoid content. Look for brands that publish up-to-date, third-party-verified third-party lab results with each batch. That's the only way to know what you're actually taking.
• A consistent daily routine with a quality product is more useful than matching doses from clinical trials that used pharmaceutical-grade IV or oral formulations in controlled settings.

WHF's CBD oil and CBD gummies are grown on our USDA Organic certified Kentucky farm, extracted and tested by independent third-party labs, and fully 2018 Farm Bill compliant. We're not a pharmaceutical company and we're not making clinical claims. But if cardiovascular health is part of why you use CBD, the underlying science behind it is more substantive than most people realize.

The next few years of clinical trials, particularly MAVERIC-2, MAVERIC-3, and ARCHER, will go a long way toward answering whether CBD earns a formal place in cardiovascular medicine. We'll be watching.

Frequently Asked Questions

Does CBD help with heart disease?

Preclinical research shows CBD has anti-inflammatory, antioxidant, and vasodilatory properties that are relevant to cardiovascular health. Animal studies have shown reduced infarct size after ischemia-reperfusion injury and decreased pericardial inflammation. The MAVERIC-Pilot clinical trial found significant pain reduction in patients with recurrent pericarditis. However, large-scale human clinical trials confirming therapeutic benefit for heart disease are still ongoing or not yet published. CBD is not a proven treatment for heart disease, and anyone with a cardiac diagnosis should work with their physician.

Does CBD lower blood pressure?

Human studies suggest CBD can produce modest blood pressure reductions. A randomized crossover trial in 70 patients with mild to moderate hypertension found CBD significantly lowered 24-hour ambulatory mean, systolic, and diastolic blood pressure after 2.5 weeks at up to 5 mg/kg per day. A smaller study found a single 600 mg dose reduced resting systolic blood pressure by about 6 mmHg. Researchers note that CBD's anxiolytic effects may contribute to these results, so whether the effect is purely vascular or partly stress-mediated remains an open question.

Is it safe to take CBD with heart medications?

CBD inhibits several CYP450 liver enzymes, which can raise or lower blood levels of medications metabolized by those enzymes. Cardiovascular drugs that may interact with CBD include warfarin, amiodarone, clopidogrel, dronedarone, certain statins (lovastatin, simvastatin), and beta-blockers such as metoprolol and nebivolol. The clinical significance of these interactions hasn't been fully quantified yet, but the potential is real. If you take any of these medications, disclose your CBD use to your prescriber before starting or continuing it.

Can CBD cause heart problems?

At typical consumer doses, CBD has a favorable safety profile in most people. At high doses, in vitro research has found CBD can prolong the cardiac action potential and QT interval, and inhibit certain ion channels that could theoretically increase arrhythmia risk in people with inherited channelopathies. However, the MAVERIC-Pilot trial in pericarditis patients found no significant QTc changes. Liver enzyme elevations were observed in some participants at very high doses (20 mg/kg per day) in one trial. For most people at standard OTC doses, serious cardiovascular adverse effects have not been documented in trials.

What type of CBD is best for heart health?

The cardiovascular trials with human evidence have primarily tested pharmaceutical-grade purified CBD in oral formulations, not full-spectrum hemp extracts. No head-to-head comparison between CBD product types exists for cardiovascular outcomes. What the research does support is that product purity and consistent dosing matter more than product format. Look for products with current third-party Certificates of Analysis showing cannabinoid potency and confirming the absence of contaminants. Oral oil formats typically allow for more precise dosing than gummies, though both can work for a consistent daily routine.